300558 贝达药业
交易中 05-17 11:17:15
资讯
新帖
简况
贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”
证券之星 · 05-11
贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”
贝达药业最新公告:BPI-16350药品注册申请获得受理
证券之星 · 05-06
贝达药业最新公告:BPI-16350药品注册申请获得受理
贝达药业(300558.SZ):BPI-16350药品注册申请获受理
智通财经 · 05-06
贝达药业(300558.SZ):BPI-16350药品注册申请获受理
贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”
证券之星 · 04-28
贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”
贝达药业:主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异
证券之星 · 04-25
贝达药业:主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异
贝达药业最新公告:BPI-16350取得Ⅲ期临床试验总结报告
证券之星 · 04-24
贝达药业最新公告:BPI-16350取得Ⅲ期临床试验总结报告
贝达药业(300558.SZ):酒石酸泰贝西利胶囊完成Ⅲ期临床试验并取得总结报告
智通财经 · 04-24
贝达药业(300558.SZ):酒石酸泰贝西利胶囊完成Ⅲ期临床试验并取得总结报告
【机构调研记录】长信基金调研恒辉安防、贝达药业等7只个股(附名单)
证券之星 · 04-24
【机构调研记录】长信基金调研恒辉安防、贝达药业等7只个股(附名单)
【机构调研记录】金元顺安基金调研贝达药业、泰恩康
证券之星 · 04-24
【机构调研记录】金元顺安基金调研贝达药业、泰恩康
【机构调研记录】浦银安盛基金调研贝达药业、世华科技等4只个股(附名单)
证券之星 · 04-24
【机构调研记录】浦银安盛基金调研贝达药业、世华科技等4只个股(附名单)
【机构调研记录】恒生前海基金调研贝达药业
证券之星 · 04-24
【机构调研记录】恒生前海基金调研贝达药业
【机构调研记录】建信基金调研蓝晓科技、贝达药业等10只个股(附名单)
证券之星 · 04-24
【机构调研记录】建信基金调研蓝晓科技、贝达药业等10只个股(附名单)
【机构调研记录】富安达基金调研贝达药业、香飘飘等3只个股(附名单)
证券之星 · 04-24
【机构调研记录】富安达基金调研贝达药业、香飘飘等3只个股(附名单)
【机构调研记录】国金基金调研贝达药业、天孚通信等3只个股(附名单)
证券之星 · 04-24
【机构调研记录】国金基金调研贝达药业、天孚通信等3只个股(附名单)
【机构调研记录】大成基金调研华恒生物、贝达药业等6只个股(附名单)
证券之星 · 04-24
【机构调研记录】大成基金调研华恒生物、贝达药业等6只个股(附名单)
【机构调研记录】同泰基金调研贝达药业
证券之星 · 04-24
【机构调研记录】同泰基金调研贝达药业
【机构调研记录】华泰柏瑞基金调研贝达药业、恒逸石化等6只个股(附名单)
证券之星 · 04-24
【机构调研记录】华泰柏瑞基金调研贝达药业、恒逸石化等6只个股(附名单)
【私募调研记录】正圆投资调研贝达药业、睿昂基因
证券之星 · 04-24
【私募调研记录】正圆投资调研贝达药业、睿昂基因
加载更多
公司概况
公司名称:
贝达药业股份有限公司
所属行业:
医药制造业
上市日期:
2016-11-07
主营业务:
贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖(两次)、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。
发行价格:
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":40.41,"timestamp":1715915835000,"preClose":40.51,"halted":0,"volume":2069900,"delay":0,"floatShares":417000000,"shares":418000000,"eps":0.9434,"marketStatus":"交易中","marketStatusCode":2,"change":-0.1,"latestTime":"05-17 11:17:15","open":40.55,"high":40.97,"low":40.31,"amount":84058800,"amplitude":0.0163,"askPrice":40.41,"askSize":2,"bidPrice":40.4,"bidSize":27,"shortable":0,"etf":0,"ttmEps":0.9434,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1715916600000},"adr":0,"adjPreClose":40.51,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":44.56,"lowLimit":36.46,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":418485885,"pbRate":3.07,"roa":"--","roe":"1.82%","epsLYR":0.83,"committee":0.554318,"marketValue":16911000000,"floatMarketCap":16857000000,"peRate":42.834428,"changeRate":-0.0025,"turnoverRate":0.005,"status":1},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2434344860","title":"贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2434344860","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434344860?lang=zh_cn&edition=full","pubTime":"2024-05-11 02:05","pubTimestamp":1715364320,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示贝达药业新获得一项发明专利授权,专利名为“免疫调节剂及其组合物和制备方法”,专利申请号为CN201980021916.6,授权日为2024年5月10日。该化合物可用于治疗,预防或改善疾病或病症,例如癌症或感染。今年以来贝达药业新获得专利授权16个,较去年同期增加了300%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051100002569.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433446815","title":"贝达药业最新公告:BPI-16350药品注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2433446815","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433446815?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:51","pubTimestamp":1714985473,"startTime":"0","endTime":"0","summary":"贝达药业公告,BPI-16350药品注册申请获得受理。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600016175.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433443938","title":"贝达药业(300558.SZ):BPI-16350药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2433443938","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433443938?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:33","pubTimestamp":1714984432,"startTime":"0","endTime":"0","summary":"智通财经APP讯,贝达药业(300558.SZ)公告,公司收到国家药品监督管理局(“NMPA”)签发的《受理通知书》,公司申报的BPI-16350(酒石酸泰贝西利胶囊)“本品联合氟维司群,适用于既往接受内分泌治疗后进展的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的局部晚期或晚期复发转移性乳腺癌患者的治疗”的上市许可申请已获得NMPA受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117531.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430672390","title":"贝达药业获得发明专利授权:“免疫调节剂及其组合物和制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430672390","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430672390?lang=zh_cn&edition=full","pubTime":"2024-04-28 02:01","pubTimestamp":1714240872,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示贝达药业新获得一项发明专利授权,专利名为“免疫调节剂及其组合物和制备方法”,专利申请号为CN201980046612.5,授权日为2024年4月26日。该化合物可用于治疗,预防或改善疾病或病症,例如癌症或感染。今年以来贝达药业新获得专利授权13个,较去年同期增加了550%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800000200.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430725134","title":"贝达药业:主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异","url":"https://stock-news.laohu8.com/highlight/detail?id=2430725134","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430725134?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:02","pubTimestamp":1714039377,"startTime":"0","endTime":"0","summary":"主营药品不同、药品生产流程不同会导致创新药企业生产周期存在差异。根据港股招股书,贝达药业耗费大量现金用于投资房地产,在2018年-2020年初,贝达药业持有投资性房地产分别为5.24亿元、5.77亿元及0.36亿元。若归属期内公司业绩水平未达到业绩考核目标条件,会冲销前期已计提的相关股份支付费用。目前BPI-16350项目尚未开展一线适应症临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500038780.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429809034","title":"贝达药业最新公告:BPI-16350取得Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2429809034","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429809034?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:41","pubTimestamp":1713951672,"startTime":"0","endTime":"0","summary":"贝达药业公告,公司自研项目BPI-16350(酒石酸泰贝西利胶囊)完成Ⅲ期临床试验后,经过一系列数据统计分析工作已取得临床试验总结报告。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400037615.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429748086","title":"贝达药业(300558.SZ):酒石酸泰贝西利胶囊完成Ⅲ期临床试验并取得总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2429748086","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429748086?lang=zh_cn&edition=full","pubTime":"2024-04-24 17:38","pubTimestamp":1713951503,"startTime":"0","endTime":"0","summary":"智通财经APP讯,贝达药业 发布公告,公司自研项目BPI-16350完成Ⅲ期临床试验后,经过一系列数据统计分析工作已取得临床试验总结报告。独立疗效委员会和研究者评估的PFS结论一致。同时,BPI-16350+氟维司群组受试者安全性良好。公司将继续做好相关新药上市准备工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108600.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122354","title":"【机构调研记录】长信基金调研恒辉安防、贝达药业等7只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122354","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122354?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:03","pubTimestamp":1713916982,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,长信基金近期对7家上市公司进行了调研,相关名单如下:1)恒辉安防 个股亮点:公司对战略新材料产业超高分子量聚Z烯纤维及其复合纤维持续投入,2)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013981.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429612236","title":"【机构调研记录】金元顺安基金调研贝达药业、泰恩康","url":"https://stock-news.laohu8.com/highlight/detail?id=2429612236","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429612236?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916973,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,金元顺安基金近期对2家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。2)泰恩康 个股亮点:?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013968.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122358","title":"【机构调研记录】浦银安盛基金调研贝达药业、世华科技等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122358","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122358?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916966,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,浦银安盛基金近期对4家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013952.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122126","title":"【机构调研记录】恒生前海基金调研贝达药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122126","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122126?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916941,"startTime":"0","endTime":"0","summary":"恒生前海基金成立于2016年,截至目前,资产管理规模(全部)129.4亿元,排名126/203;资产管理规模(非货币)129.4亿元,排名124/203;管理基金数41只,排名107/203;旗下基金经理6人,排名136/203。旗下最近一年表现最佳的基金产品为恒生前海港股通高股息指数,最新单位净值为0.92,近一年增长13.56%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013914.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429223681","title":"【机构调研记录】建信基金调研蓝晓科技、贝达药业等10只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429223681","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429223681?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916938,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,建信基金近期对10家上市公司进行了调研,相关名单如下:1)蓝晓科技 个股亮点:蓝晓转02于2023-05-08上市;公司在多肽固相合成载体领域已成为国内外主要品牌供应商。旗下最新募集产品为建信开元金享6个月持有期债券发起A,类型为债券型-混合二级,集中认购期2024年4月11日至2024年4月30日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013910.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122334","title":"【机构调研记录】富安达基金调研贝达药业、香飘飘等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122334","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122334?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916932,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,富安达基金近期对3家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013902.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122357","title":"【机构调研记录】国金基金调研贝达药业、天孚通信等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122357","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122357?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916927,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,国金基金近期对3家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013895.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429112233","title":"【机构调研记录】大成基金调研华恒生物、贝达药业等6只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429112233","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429112233?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:02","pubTimestamp":1713916927,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,大成基金近期对6家上市公司进行了调研,相关名单如下:1)华恒生物 华恒生物2024年一季报显示,公司主营收入5.01亿元,同比上升25.12%;归母净利润8657.41万元,同比上升6.62%;扣非净利润8591.07万元,同比上升9.7%;负债率56.65%,财务费用460.23万元,毛利率33.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013894.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429350122","title":"【机构调研记录】同泰基金调研贝达药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2429350122","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429350122?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:01","pubTimestamp":1713916911,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,同泰基金近期对1家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013876.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429122301","title":"【机构调研记录】华泰柏瑞基金调研贝达药业、恒逸石化等6只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429122301","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429122301?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:01","pubTimestamp":1713916905,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月23日披露的机构调研信息,华泰柏瑞基金近期对6家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400013866.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429225321","title":"【私募调研记录】正圆投资调研贝达药业、睿昂基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2429225321","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429225321?lang=zh_cn&edition=full","pubTime":"2024-04-24 08:00","pubTimestamp":1713916847,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月23日披露的机构调研信息,知名私募正圆投资近期对2家上市公司进行了调研,相关名单如下:1)贝达药业 个股亮点:公司在研新药项目包括30多个国家一类及二类新药,有8个项目进入临床试验阶段;17年2月与杭州瑞普基因科技有限公司签订合作协议,合作方拥有领先的基因检测平台和生物信息大数据分析平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240801308b4c6ed7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240801308b4c6ed7&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","stockEarnings":[{"period":"1week","weight":-0.0835},{"period":"1month","weight":0.1191},{"period":"3month","weight":-0.0495},{"period":"6month","weight":-0.3082},{"period":"1year","weight":-0.4013},{"period":"ytd","weight":-0.2142}],"companyName":"贝达药业股份有限公司","boardCode":"AI0027","perCapita":"13666股","boardName":"医药制造业","registeredCapital":"41848万元","compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.0384},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.0223},{"period":"1year","weight":-0.0493},{"period":"ytd","weight":0.0496}],"survey":" 贝达药业股份有限公司主营业务为创新药物的生产与销售。公司主要产品和服务有贝安汀、贝美纳、凯美纳、赛美纳、伏美纳。公司明星产品凯美纳获得了国家知识产权局和世界专利组织联合颁发的中国专利金奖(两次)、我国工业界“奥斯卡奖”、中国工业大奖、人民网和中国药促会联合颁发的最具临床价值创新药奖、入选新中国70年卫生健康大事记等。荣获2022浙江省药学会科学技术特等奖。","serverTime":1715915837037,"listedPrice":17.57,"stockholders":"30523人(较上一季度增加9.33%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}